Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

Abstract Background The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments. However, this reimbursement policy should b...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Patricia Pozo-Rosich, José Luis Poveda, Carlos Crespo, María Martínez, José Manuel Rodríguez, Pablo Irimia
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-03-01
סדרה:	The Journal of Headache and Pain
נושאים:	Chronic migraine Episodic migraine Topiramate Erenumab Cost-effectiveness Spain
גישה מקוונת:	https://doi.org/10.1186/s10194-024-01747-w
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!